NFE2L2 and Friedreich ataxia: Omaveloxone is an Nrf2 activator demonstrated to rescue mitochondrial defects in animal models of FRDA as well as in FRDA patient fibroblasts [109] Interestingly, omaveloxone is also under trial to prevent corneal endothelial cell loss in patients undergoing cataract surgery (www.clinicaltrials.gov).